Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry
Por:
de Isla, L, Arroyo-Olivares, R, Alonso, R, Muniz-Grijalvo, O, Diaz-Diaz, J, Zambon, D, Fuentes, F, Mata, N, Piedecausa, M, Manas, M, Munoz-Torrero, J, Miramontes-Gonzalez, J, de Andres, R, Mauri, M, Aguado, R, Brea, A, Cepeda, J, Vidal-Pardo, J, Martinez-Faedo, C, Barba, M, Argueso, R, Ruiz-Perez, E, Michan, A, Arrieta, F, Fernandez, M, Perez, L, Pinilla, J, Diaz-Soto, G, Pinto, X, Padro, T, Badimon, L, Mata, P and Invest SAFEHEART
Publicada:
1 oct 2020
Categoría:
Cardiology and cardiovascular medicine
Resumen:
Introduction and objectives: The SAFEHEART study was designed to analyze the situation of familial heterozygous hypercholesterolemia (FHH) and improve knowledge of this disease in Spain. Our objective was to determine the incidence rate of cardiovascular events, the estimated risk of developing an event and its modification, the use of lipid-lowering treatment, and the achievement of low-density lipoprotein cholesterol targets in patients with FHH.
Methods: SAFEHEART is a prospective, open, multicenter, nationwide cohort study, with long-term protocol-based follow-up in a population of individuals with molecularly-characterized FHH. We analyzed patients older than 18 years with complete follow-up.
Results: We included 2648 patients with FHH. The median follow-up was 6.6 (4.8-9.7) years. The overall incidence rate of cardiovascular events was 1.3 events/100 patient-years. After the follow-up, the 10-year estimated risk of developing a cardiovascular event was reduced from 1.6% to 1.3% (P <.001). In the last follow-up, 20.6% and 22.2% of the patients in primary and secondary prevention achieved low-density lipoprotein cholesterol values < 100 mg/dL and < 70 mg/dL, respectively.
Conclusions: This study was performed in the largest population of patients with FHH in Spain. We identified the incidence rate of cardiovascular events, the estimated risk of developing a cardiovascular event and its modification, the achievement of low-density lipoprotein cholesterol targets, and the therapeutic management in this population. Although the cardiovascular risk of FHH is high, appropriate treatment reduces the likelihood of an event. (C) 2019 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L.U. All rights reserved.
Filiaciones:
de Isla, L:
Hosp Clin San Carlos, Serv Cardiol, IDISSC, Madrid, Spain
Fdn Hipercolesterolemia Familiar, Gen Alvarez de Castro 14, Madrid 28010, Spain
Arroyo-Olivares, R:
Fdn Hipercolesterolemia Familiar, Gen Alvarez de Castro 14, Madrid 28010, Spain
Alonso, R:
Fdn Hipercolesterolemia Familiar, Gen Alvarez de Castro 14, Madrid 28010, Spain
Clin Las Condes, Dept Nutr, Santiago, Chile
Muniz-Grijalvo, O:
Hosp Virgen del Rocio, Serv Med Interna, Seville, Spain
Diaz-Diaz, J:
Hosp Abente & Lago, Serv Med Interna, La Coruna, Spain
Zambon, D:
Hosp Clin Barcelona, Serv Endocrinol, Barcelona, Spain
Fuentes, F:
Hosp Univ Reina Sofia, Unidad Lipidos & Arteriosclerosis, IMIBIC, Cordoba, Spain
Mata, N:
Consejeria Sanidad, Dept Epidemiol, Madrid, Spain
Piedecausa, M:
Hosp Elche, Serv Med Interna, Alicante, Spain
Manas, M:
Hosp Gen Univ Ciudad Real, Serv Med Interna, Ciudad Real, Spain
Munoz-Torrero, J:
Hosp San Pedro de Alcantara, Serv Med Interna, Caceres, Spain
Miramontes-Gonzalez, J:
Hosp Clin Salamanca, Serv Med Interna, Salamanca, Spain
de Andres, R:
Fdn Jimenez Diaz, Serv Med Interna, Madrid, Spain
Mauri, M:
Hosp Terrassa, Serv Med Interna, Barcelona, Spain
Aguado, R:
Hosp Univ Leon, Serv Endocrinol, Leon, Spain
Brea, A:
Hosp San Pedro, Serv Med Interna, Logrono, Spain
:
Hosp Comarcal Vega Baja, Serv Med Interna, Alicante, Spain
Vidal-Pardo, J:
Hosp Lucus Augusti, Serv Endocrinol, Lugo, Spain
Martinez-Faedo, C:
Hosp Cent Asturias, Serv Endocrinol, Oviedo, Asturias, Spain
Barba, M:
Hosp Gen Albacete, Serv Med Interna, Albacete, Spain
Argueso, R:
Hosp Lucus Augusti, Serv Endocrinol, Lugo, Spain
Ruiz-Perez, E:
Hosp Univ Burgos, Serv Endocrinol, Burgos, Spain
Michan, A:
Hosp Jerez Frontera, Serv Med Interna, Cadiz, Spain
Arrieta, F:
Hosp Ramon & Cajal, Serv Endocrinol, Madrid, Spain
Fernandez, M:
Hosp Cabuenes, Serv Endocrinol, Gijon, Asturias, Spain
Perez, L:
Hosp Univ Alava, Serv Endocrinol, Vitoria, Spain
Pinilla, J:
Ctr Salud San Miguel Salinas, Alicante, Spain
Diaz-Soto, G:
Hosp Clin Univ, Serv Endocrinol, Valladolid, Spain
Pinto, X:
Hosp Bellvitge Princeps Espanya, Serv Med Interna, Barcelona, Spain
Padro, T:
Hosp Santa Creu & Sant Pau, IIB St Pau, Inst Recerca, Barcelona, Spain
Badimon, L:
Hosp Santa Creu & Sant Pau, IIB St Pau, Inst Recerca, Barcelona, Spain
Mata, P:
Fdn Hipercolesterolemia Familiar, Gen Alvarez de Castro 14, Madrid 28010, Spain
Open Access
FULL TEXT
 |
Published Version |
This policy does not allow for Open Access for this version |
| No Accesible |
|